Abstract:
The invention relates to the use of cyclic compounds as ligands of integrin receptors, in particular as ligands of the alpha vss3 integrin receptor. The invention also relates to the novel compounds, to the use thereof and to pharmaceutical preparations which contain said compounds. Examples of said compounds include benzazepines, benzodiazepines and thieno[3,2-b]azepines, used for treating arteriosclerosis, rheumatoid arthritis, restenosis after vessel damage or stent implantation, angioplasty, acute kidney failure, microangiopathy associated with angiogenesis, diabetic angiopathy, thrombocyte-mediated vascular occlusion, arterial thrombosis, congestive heart-failure, myocardial infarct, apoplexy, cancer, osteoporosis, hypertension, psoriasis or viral, parasitic or bacterial diseases, inflammation, wound healing, hyperparathyroidism, Paget's bone disease, malignant hypercalcemia, or metastatic osteolytic lesions.
Abstract:
The invention relates to novel compounds that bind to integrin receptor ligands. The invention also relates to the production thereof, to their use as integrin receptor ligands and to their use for treating diseases, to pharmaceutical preparations that contain said compounds and to pharmaceutical preparations that contain at least one additional active compound.
Abstract:
The invention relates to ancrod specific monoclonal antibodies, antibody fragments, mixtures or derivatives thereof and the use thereof in pharmaceutical preparations or in diagnostics. The invention also relates to cells which express said antibodies, antibody fragments and mixtures or derivatives thereof.
Abstract:
The invention relates to the use of an endothelin blocker in combination with an alpha v beta 3 integrin receptor antagonist for the treatment or prevention of diseases, particularly to the use of a pharmaceutical composition, comprising an endothelin blocker and an alpha v beta 3 integrin receptor antagonist, for the treatment or prevention of cardiovascular disorders, particularly for the treatment or prevention of restenosis after vessel injury or revascularisation treatment and to the pharmaceutical composition itself.
Abstract:
The invention relates to the use of modulators of cytokine mediated signalling pathways in combination with integrin alpha v beta 3 receptor antagonists for the treatment or prevention of diseases, particularly to the use of pharmaceutical composition, comprising a modulator of cytokine mediated signalling pathways and an integrin alpha v beta 3 receptor antagonist, for the treatment or prevention of inflammatory or autoimmune disorders, particularly for the treatment or prevention of rheumatoid arthritis and to the pharmaceutical composition itself.
Abstract:
The invention relates to novel compounds which bind to integrin receptors, in particular as ligands for the alpha V beta 3 integrin receptor, the use thereof and pharmaceutical preparations containing said compounds.
Abstract:
The invention relates to novel compounds of formula (I) which bind to integrin receptors, wherein G and L have the following meaning: L is a structural element of formula IL, wherein T represents a COOH group or a radical that can be hydrolyzed to obtain COOH and U- represents (XL)a-(CRL RL )b-, -CRL =CRL -, ethylene or =CRL -, wherein a is 0 or 1; b is 0, 1 or 2; XL represents CRL RL , NRL , oxygen or sulfur and G is a structural element of formula IG, wherein the insertion of structural element G can occur in both orientations and XO represents nitrogen or CRG . The invention also relates to the production of said compounds and to their use as medicaments.
Abstract:
The invention relates to novel compounds of formula (I) which bind to integrin receptors, wherein G and L have the following meaning: L is a structural element of formula IL, wherein T represents a COOH group or a radical that can be hydrolyzed to obtain COOH and U- represents (XL)a-(CRL RL )b-, -CRL =CRL -, ethylene or =CRL -, wherein a is 0 or 1; b is 0, 1 or 2; XL represents CRL RL , NRL , oxygen or sulfur and G is a structural element of formula IG, wherein the insertion of structural element G can occur in both orientations and XO represents nitrogen or CRG . The invention also relates to the production of said compounds and to their use as medicaments.
Abstract:
The invention relates to prodrugs of pharmacologically active, five-membered heterocyclic amidines from which in vivo compounds are obtained, these compounds being competitive inhibitors of trypsin-type serin proteases, especially thrombin and kininogenases such as kallikrein. The invention also relates to the production of these prodrugs and to their use as medicaments, to pharmaceutical compositions that contain the prodrugs of the active compounds as components, and to the use of the compounds as thrombin inhibitors, anticoagulants and anti-inflammatory agents.
Abstract:
The invention relates to prodrugs of pharmacologically active, five-membered heterocyclic amidines from which in vivo compounds are obtained, these compounds being competitive inhibitors of trypsin-type serin proteases, especially thrombin and kininogenases such as kallikrein. The invention also relates to the production of these prodrugs and to their use as medicaments, to pharmaceutical compositions that contain the prodrugs of the active compounds as components, and to the use of the compounds as thrombin inhibitors, anticoagulants and anti-inflammatory agents.